ALMS · NASDAQ · Biotechnology

Alumis (ALMS)

Develops oral TYK2 therapies for immune-mediated diseases in the body and brain.

$7.37
vs last close−0.75 (−9.19%)

Something off on this page? Send us feedback.

Next report
Nov 12, 26
estimated · in 50 days
EPS estimate
−$0.73
Revenue estimate
$1.9M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.74−$1.82−$1.17−$1.06−$0.95−$0.74−$1.11Pending
Estimate−$1.40−$1.47−$1.11−$0.92−$0.97−$0.74−$0.77−$0.73
Surprise−24.3%−23.8%−5.4%−15.2%+2.1%+0.4%−44.7%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$1.5M$17.4M$2.7M$2.1M$1.9M$1.7M$1.7MPending
Estimate$1.0M$1.7M$3.1M$2.8M$2.4M$2.1M$3.7M$1.9M
Surprise+51.8%+943.3%−15.2%−24.9%−18.4%−15.4%−54.5%

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Mar 2028−$4.49
Dec 2027−$0.63
Sep 2027−$0.65
Jun 2027−$0.70
Mar 2027−$0.70
Dec 2026−$0.73
Nov 2026−$0.73
Aug 2026−$0.77−$1.11−44.7%
May 2026−$0.74−$0.74+0.4%
Mar 2026−$0.97−$0.95+2.1%
Nov 2025−$0.92−$1.06−15.2%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023

The latest year is open to everyone — the 11 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Mar 2028−$4.49$1.7M
Dec 2027−$0.63$11.8M
Sep 2027−$0.65$4.6M
Jun 2027−$0.70$750.0K
Mar 2027−$0.70$750.0K
Dec 2026−$0.73$1.9M
Nov 12, 2026−$0.73$1.9M
Aug 13, 2026−$0.77−$1.11−44.7%$3.7M$1.7M−54.5%+3.7%
May 14, 2026−$0.74−$0.74+0.4%$2.1M$1.7M−15.4%−7.2%
Mar 19, 2026−$0.97−$0.95+2.1%$2.4M$1.9M−18.4%−0.2%
Nov 13, 2025−$0.92−$1.06−15.2%$2.8M$2.1M−24.9%+0.8%
Aug 13, 2025
May 14, 2025
Mar 19, 2025
Nov 13, 2024
Aug 13, 2024
Jun 7, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 29, 2023
Mar 31, 2023

The latest year is open to everyone — the 11 quarters behind it read with an account.